Login / Signup

LOXL1 promotes tumor cell malignancy and restricts CD8 + T cell infiltration in colorectal cancer.

Chenxi LiSiqi ChenXiaona FangYaqing DuXin-Yuan GuanRunhua LinLiang XuPing LanQian Yan
Published in: Cell biology and toxicology (2024)
Our findings underscore the critical role of LOXL1 in modulating both malignancy and immunosuppression in CRC. This positions LOXL1 as a promising biomarker for predicting prognosis and the response to immunotherapy in CRC patients.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • prognostic factors
  • single cell
  • bone marrow